North America Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018 To 2023)

North America Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018 To 2023)

ID: 7840 | Pages: 145 | April 2018 | Region: North America


North America Overactive Bladder Treatment Market was worth USD 3.7 billion in 2017 and is projected to grow at a CAGR of 3.1%, to reach USD 4.3 billion by 2022. Overactive bladder is the condition in which the person has an urge to urinate frequently. Overtime, this might lead to the loss of bladder control and this condition is called urge incontinence. People generally neglect this condition for years before it becomes a severe inconvenience.

The actual causes for this condition are not known. Initial treatment to this condition generally includes bladder training, pelvic floor exercises and behavioral methods. Medications and neurostimulations are recommended if other methods do not work. Also, there are procedures which use medical devices such as Urgent PC Neuromodulation system, injectables and surgical interventions are used for people with neurological conditions.

Due to the increasing number of people with neurological diseases, especially among geriatric population, the demand for overactive bladder treatment has increased. Availability of innovative therapies and increasing pharmaceutical companies are driving the market growth. However, lack of awareness about the condition as well as the treatments available and side effects associated with the usage of drugs are hindering the market growth.

The Overactive Bladder Treatment market is segmented by treatment, disease and region. Based on the treatment, the market is segmented into Mirabegron, Anticholinergics, Botox, Intravesical Instillation and Neurostimulation. Anticholinergics are further categorized into Solifenacin, Fesoterodine, Tolterodine, Oxybutynin, Darifenacin, Trospium and Other Anticholinergics. Anticholinergics segment holds the largest market share as they are the most frequently used medication for the treatment of OAB. Botox segment is rapidly growing after its approval by FDA for neurological conditions. By Disease, the market is categorized into Neurogenic Overactive Bladder, Idiopathic Overactive Bladder. Neurogenic Overactive Bladder is further categorized into Overactive Bladder in Stroke, Spinal Cord Injury, Parkinson's disease, Multiple Sclerosis and Other Disorders. Neurogenic Overactive Bladder is the most prevalent condition among aging population due to the high neurological disorders.

On the basis of region, the North America Overactive Bladder Treatment market is segmented into US and Canada. North America leads the OAB market. The condition is reported to be prevalent in high percentage of population in this region. Highly developed healthcare infrastructure resulted in availability of innovative treatments.

Some of the major players in Overactive Bladder Treatment market are Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V, Sanofi, Aurobindo Pharma Ltd, and Endo International.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Treatment                  

                                5.1.1 Introduction           

                                5.1.2 Mirabegron            

                                5.1.3 Anticholinergics    

                                                5.1.3.1 Solifenacin

                                                5.1.3.2 Fesoterodine

                                                5.1.3.3 Tolterodine

                                                5.1.3.4 Oxybutynin

                                                5.1.3.5 Darifenacin

                                                5.1.3.6 Trospium

                                                5.1.3.7 Other Anticholinergics

                                5.1.4 Botox        

                                5.1.5 Intravesical Instillation       

                                5.1.6 Neurostimulation 

                                5.1.7 Y-o-Y Growth Analysis, By Treatment          

                                5.1.8 Market Attractiveness Analysis, By Treatment        

                                5.1.9 Market Share Analysis, By Treatment         

                5.2 Disease                        

                                5.2.1 Introduction           

                                5.2.2 Neurogenic Overactive Bladder     

                                                5.2.2.1 Stroke

                                                5.2.2.2 Spinal Cord Injury

                                                5.2.2.3 Parkinson's disease

                                                5.2.2.4 Multiple Sclerosis

                                                5.2.2.5 Other Disorders

                                5.2.3 Idiopathic Overactive Bladder         

                                5.2.4 Y-o-Y Growth Analysis, By Disease                

                                5.2.5 Market Attractiveness Analysis, By Disease              

                                5.2.6 Market Share Analysis, By Disease               

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Treatment

                                                6.1.3.3 By Disease

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Treatment

                                                6.1.4.3 By Disease

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Treatment

                                                6.1.5.3 By Disease

                6.2 United States                            

                6.3 Canada                         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Pfizer                            

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Allergan Plc                 

                8.3 Hisamitsu Pharmaceutical                    

                8.4 Johnson & Johnson                 

                8.5 Astellas Pharma Inc                 

                8.6 Teva Pharmaceutical Industries                         

                8.7 Mylan N.V                   

                8.8 Sanofi                           

                8.9 Aurobindo Pharma Ltd                          

                8.10 Endo International                

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. North America Overactive Bladder Treatment Market By Treatment, From 2018-2023 ( USD Billion )
  2. North America Mirabegron Market By Region, From 2018-2023 ( USD Billion )
  3. North America Anticholinergics Market By Region, From 2018-2023 ( USD Billion )
  4. North America Botox Market By Region, From 2018-2023 ( USD Billion )
  5. North America Intravesical Instillation Market By Region, From 2018-2023 ( USD Billion )
  6. North America Neurostimulation Market By Region, From 2018-2023 ( USD Billion )
  7. North America Overactive Bladder Treatment Market By Disease, From 2018-2023 ( USD Billion )
  8. North America Neurogenic Overactive Bladder Market By Region, From 2018-2023 ( USD Billion )
  9. North America Idiopathic Overactive Bladder Market By Region, From 2018-2023 ( USD Billion )
  10. United States Overactive Bladder Treatment Market By Treatment, From 2018-2023 ( USD Billion )
  11. United States Overactive Bladder Treatment Market By Disease, From 2018-2023 ( USD Billion )
  12. Canada Overactive Bladder Treatment Market By Treatment, From 2018-2023 ( USD Billion )
  13. Canada Overactive Bladder Treatment Market By Disease, From 2018-2023 ( USD Billion )
  14. North America Overactive Bladder Treatment Market By Anticholinergics, From 2018-2023 ( USD Billion )
  15. North America Solifenacin Market By Region, From 2018-2023 ( USD Billion )
  16. North America Fesoterodine Market By Region, From 2018-2023 ( USD Billion )
  17. North America Tolterodine Market By Region, From 2018-2023 ( USD Billion )
  18. North America Oxybutynin Market By Region, From 2018-2023 ( USD Billion )
  19. North America Darifenacin Market By Region, From 2018-2023 ( USD Billion )
  20. North America Trospium  Market By Region, From 2018-2023 ( USD Billion )
  21. North America Other Anticholinergics Market By Region, From 2018-2023 ( USD Billion )
  22. United States Overactive Bladder Treatment Market By Anticholinergics, From 2018-2023 ( USD Billion )
  23. Canada Overactive Bladder Treatment Market By Anticholinergics, From 2018-2023 ( USD Billion )
Middle East And Africa Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Ov...
Latin America Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive ...
Asia-pacific Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive B...
Europe Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder...
North America Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive ...
Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder) And B...
Middle East And Africa Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Lab...
Latin-America Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories...
Asia-Pacific Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories,...
Europe Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories, Refer...
North-America Blood Culture Tests Market by Method (Automated, Manual), Product (Consumables, Instrument), Technology (Culture-based, PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospit...
Blood Culture Tests Market By Product Type (Gait Belts & Lift Vests, Canes, Crutches, Walker, Wheelchairs, Power Scooters), And Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018 To ...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.